28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Long non-coding RNA (lncRNA) SNHG5 has been found to play an important role in tumors. Nevertheless, the function and mechanism of lncRNA SNHG5 in osteosarcoma (OS) remains unclear. The purpose of this study was to investigate whether lncRNA SNHG5 can regulate the occurrence and development of OS cells.

          Methods

          We performed quantitative real time PCR to detect the expression of lncRNA SNHG5 in OS cells. 143B, MG63 (knockdown) and U2OS, U2R (overexpression) cell lines were chosen for the function study of SNHG5. The effect of SNHG5, miR-212-3p, and SGK3 in OS cells was explored by MTT assays, clony formation, flow cytometry, transwell assays, wound healing assays, and cell spreading assays. Quantitative real-time PCR, Western blot analysis and luciferase assays were used to detect the interaction between lncRNA SNHG5 and miR-212-3p.

          Results

          In this study, knockdown of lncRNA SNHG5 suppressed the growth and metastasis of OS cells, whereas the overexpression of SNHG5 produced an opposite result. Mechanistically, lncRNA SNHG5 functions as a sponger against miR-212-3p and suppresses the miR-212-3p/SGK3 signaling pathway. Introduction of miR-212-3p mimics or inhibitors reverses SNHG5 overexpression or silences the exerted tumor promoting or suppressing effect. In addition, our results showed that the function of SNHG5 can be rescued by miR-212-3p and can regulate the growth and metastasis of OS cells via SGK3, the downstream target of miR-212-3p.

          Conclusions

          In summary, our study demonstrated that lncRNA SNHG5 can regulate the proliferation and metastasis of OS cells through the miR-212-3p/SGK3 axis. This axis may provide a new target for future clinical treatment.

          Electronic supplementary material

          The online version of this article (10.1186/s12935-018-0641-9) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Epithelial-mesenchymal transitions in development and disease.

          The epithelial to mesenchymal transition (EMT) plays crucial roles in the formation of the body plan and in the differentiation of multiple tissues and organs. EMT also contributes to tissue repair, but it can adversely cause organ fibrosis and promote carcinoma progression through a variety of mechanisms. EMT endows cells with migratory and invasive properties, induces stem cell properties, prevents apoptosis and senescence, and contributes to immunosuppression. Thus, the mesenchymal state is associated with the capacity of cells to migrate to distant organs and maintain stemness, allowing their subsequent differentiation into multiple cell types during development and the initiation of metastasis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Osteosarcoma.

            The successful treatment of patients with osteosarcoma requires close cooperation within an experienced multidisciplinary team including pediatric or medical oncologists, surgeons, pathologists and radiologists. Therefore, therapy should be performed in specialized centers able to provide access to the full spectrum of care. As in other rare malignancies, treatment should be administered within prospective multicenter trials. Therapy must include complete surgical removal of all detectable tumor sites as well as multiagent chemotherapy. The chemotherapy regimen should include several or all of the following four drugs: doxorubicin, high-dose methotrexate with leukovorin-rescue, cisplatin and ifosfamide. Preoperative (neoadjuvant) plus postoperative (adjuvant) polychemotherapy should be preferred, because it allows preparation for safe surgery and preparation of the appropriate prosthesis for the individual patient. The choice of the postponed definitive surgical procedure should be influenced by the anatomical site of the primary tumor, its relationship to neighboring structures, such as vessels and nerves, age and growth potential of the patient, and probably also by the response of the tumor to preoperative chemotherapy. A major, as yet unsolved, problem is the dismal prognosis for patients with unresectable or relapsed osteosarcomas. Novel approaches are needed in order to improve their prognosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Osteosarcoma.

              Osteosarcoma is a malignant tumor that primarily affects the long bones but can also involve other bones in the body.  It has a bimodal distribution with peaks in the second decade of life and late adulthood.  This chapter will highlight the clinical presentation, diagnosis, and treatment of osteosarcoma.
                Bookmark

                Author and article information

                Contributors
                jcd4579155@163.com
                riozhou@163.com
                397931314@qq.com
                18179853251@163.com
                123776922@qq.com
                kkc67@cornell.edu
                474748958@qq.com
                409219690@qq.com
                66031226@qq.com
                ndsfy001425@ncu.edu.cn
                nclvxiaobin@sina.cn
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                18 September 2018
                18 September 2018
                2018
                : 18
                : 141
                Affiliations
                [1 ]GRID grid.479689.d, Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, , The Third Affiliated Hospital of Nanchang University, ; 128 Xiangshan Northern Road, Nanchang, 330008 Jiangxi People’s Republic of China
                [2 ]GRID grid.479689.d, Department of Orthopedics, , The Third Affiliated Hospital of Nanchang University, ; 128 Xiangshan Northern Road, Nanchang, 330008 Jiangxi People’s Republic of China
                [3 ]ISNI 0000 0001 2182 8825, GRID grid.260463.5, Medical Department of Graduate School, , Nanchang University, ; Nanchang, 330006 Jiangxi People’s Republic of China
                [4 ]ISNI 0000 0001 2182 8825, GRID grid.260463.5, First Clinical Department, , Medical School of Nanchang University, ; Nanchang, 330006 Jiangxi People’s Republic of China
                Article
                641
                10.1186/s12935-018-0641-9
                6145323
                30250399
                bd63fadc-ce15-4e20-86f3-a2f9dc1b18f0
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 1 June 2018
                : 10 September 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81560452
                Award ID: 81672866
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100004479, Natural Science Foundation of Jiangxi Province;
                Award ID: 20161BAB205192
                Award ID: 20171ACB21073
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100010251, Youth Science Foundation of Jiangxi Province;
                Award ID: 20122BAB215028
                Award Recipient :
                Funded by: Excellent Youth Foundation of Jiangxi Scientific Committee
                Award ID: 20162BCB23001
                Award Recipient :
                Funded by: Science and Research Fund of Jiangxi Health and Family Planning Commission
                Award ID: 20164002
                Award Recipient :
                Funded by: The Foundation of Nanchang Science and Technology Bureau
                Award ID: 2016 ZSCX009
                Award Recipient :
                Categories
                Primary Research
                Custom metadata
                © The Author(s) 2018

                Oncology & Radiotherapy
                lncrna snhg5,mir-212-3p,osteosarcoma,sgk3,cell proliferation,cell invasion and migration

                Comments

                Comment on this article